## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.6% below STRENGTH zone (4.0-10.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($141.24)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 3, Bearish: 0)

**1. Agilent Technologies price driven lower by pivotal resistance - Forecast today - 02-12-2025**
- Source: Economies.com | 20251202T132500 | Somewhat-Bullish | Relevance: 100%
- Agilent Technologies (A) declined after hitting a pivotal resistance level at $153.75, prompting profit-taking despite an overall short-term ascending trend. The stock is attempting to relieve overbought RSI saturation and consolidate positive momentum. A breakout above $153.75 is needed to target the next resistance at $169.50, with a bullish forecast.

**2. Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight**
- Source: BioSpace | 20251202T103950 | Bullish | Relevance: 100%
- Agilent Technologies announced new 21 CFR Part 11 compliance software for its xCELLigence Real-Time Cell Analysis (RTCA) eSight system. This upgrade extends the system's usability from drug discovery to GMP-regulated manufacturing and quality control settings by adding security features like user authentication, electronic signatures, and audit trails. The software addresses the growing need for regulatory-ready digital lab tools in biopharma and cell therapy manufacturing, ensuring data integrity and streamlining regulatory submissions.

**3. Agilent Technologies (NYSE: A) CEO surrenders 1,948 shares for taxes**
- Source: Stock Titan | 20251201T163400 | Neutral | Relevance: 100%
- Agilent Technologies' President and CEO, Padraig McDonnell, surrendered 1,948 shares of common stock on November 26, 2025, to cover tax liabilities arising from the vesting of restricted stock units. This transaction, executed at $154.37 per share, is described as a routine administrative act to satisfy taxes, not an open-market sale. After this surrender, the CEO beneficially owns 66,539 shares of Agilent common stock.

**4. Agilent Technologies (A) VP Gonsalves discloses 3,000-share sale and gifts**
- Source: Stock Titan | 20251201T162900 | Somewhat-Bearish | Relevance: 100%
- Rodney Gonsalves, Vice President and Corporate Controller of Agilent Technologies, reported a sale of 3,000 shares of Agilent common stock at a weighted average price of $154.9853 per share on November 26, 2025. He also surrendered 119 shares for tax liabilities related to restricted stock unit vesting and disclosed gift-related transfers involving 200 shares to the Gonsalves Family Charitable Gift Fund. Following these transactions, he directly owned 31,526.6872 shares and indirectly held 40.192 shares through the Gonsalves Trust.

**5. Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight**
- Source: WebWire | 20251201T142636 | Bullish | Relevance: 100%
- Agilent Technologies (NYSE: A) has released new 21 CFR Part 11 compliance software for its xCELLigence RTCA eSight system, enabling its use in GMP-regulated manufacturing and quality control settings in addition to drug discovery labs. This upgrade provides enhanced security features, including audit trails, electronic signatures, and secure user authentication, addressing the growing demand for regulatory-ready digital lab tools in biopharma and cell therapy manufacturing. The software aims to support continuity from early-stage research to production, ensuring data integrity and audit-readiness across the drug development pipeline.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |
| 2025-11-25 | UBS | $180 | $170 | +6% |
| 2025-11-25 | Wells Fargo | $175 | $150 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |
| 2025-11-25 | UBS | main | Buy |
| 2025-11-25 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 22.7x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.2B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 22.7 |
| Current P/E | 25.1 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.7% to -1.6% (-5.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.6pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 53. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.63% (CS: 34) | Neutral |
| RSI_14 | 53.4 | Neutral |
| MACD Histogram | -0.33 | Bearish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.206x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $149.26
- **Stop Loss:** $141.24 (5.4% risk)
- **Target:** $157.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 118
- **Position Value:** $17,612.68
- **Portfolio %:** 17.61%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*